Document:

<PAGE>   1
                                                                   EXHIBIT 10.27

                           TOLL MANUFACTURE AGREEMENT

This Agreement [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**] by and between

Organon Inc., a corporation duly organized and existing under the laws of New
Jersey (USA) and having its registered offices at 375 Mt. Pleasant Ave., West
Orange, New Jersey 07052, USA on the one hand, hereinafter referred to as
"Organon,"

And

CIMA LABS Inc., a corporation duly organized and existing under the laws of the
State of Delaware and having its principal offices at 10000 Valley View Road,
Eden Prairie, Minnesota 55344, USA, hereinafter referred to as "Manufacturer."

Organon and Manufacturer may hereinafter be referred to as "Party," or
collectively as "Parties."

WHEREAS:

     A.   An Affiliated Company of Organon and Manufacturer have entered into a
          License Agreement dated [**CONFIDENTIAL TREATMENT REQUESTED, PORTION
          OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
          COMMISSION.**], whereby Manufacturer granted Organon and/or Organon's
          Affiliated Companies a license to, among others, make the Product (as
          hereinafter defined) under certain conditions;

     B.   Organon wishes Manufacturer to manufacture the Product on its behalf;

     C.   Manufacturer has knowledge and sufficient capacity to manufacture the
          Product based on Product forecast supplied to Manufacturer by Organon,
          and is willing to perform such manufacturing under the terms and
          conditions as contained herein.

NOW, THEREFORE, in consideration of the foregoing and the mutual agreement as
set forth herein, the Parties agree as follows:

                                      1
<PAGE>   2
                                                                   EXHIBIT 10.27

Section 1:  DEFINITIONS

Whenever used in this Agreement, unless otherwise clearly required by the
context, the following terms shall have the meaning as defined hereinafter (in
alphabetical order) and shall include both the single and the plural.

1.1      The term "Affiliated Company" shall mean any company which by means of
         a majority of shares or otherwise, either directly or indirectly,
         controls, is controlled by or is under common control with either Party
         hereto.

1.2      The term "Effective Date" shall mean the date first written above.

1.3      The term "Manufacturing Know-How" shall mean and include any and all
         data, information and any experience or other data, in the possession
         of the Manufacturer necessary for Organon to effectively and
         efficiently manufacture the Product.

1.4      The term "License Agreement" shall mean the license agreement
         referenced under preamble A above.

1.5      The term "GMP Agreement" shall mean: the agreements entitled "Agreement
         On Tasks And The Division Of Responsibilities In Contract
         Manufacturing" Between NV Organon and Manufacturer and between Organon
         and Manufacturer, as amended from time to time, which is incorporated
         by reference herein.

1.6      The term "Product" shall mean an effervescent prescription tablet in
         [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**] mg mirtazapine(R)
         dosage strengths, manufactured using the technology of the Manufacturer
         commonly known as Orasolv(R), containing the Substance as the sole
         active ingredient and adapted to disperse in the mouth of a human
         adult, which tablet incorporates the Substance together with a matrix
         or coating in microparticles or microcapsules which provide essentially
         complete release of the Substance into the gastrointestinal tract in a
         period of less than one hour after dissolution of the tablet, which is
         packaged utilizing PakSolv(TM) technology.

1.7      The term "Specifications" shall mean the specifications for the Product
         as set forth in the Remeron(R) Soltab(TM) NDA as amended and as
         supplemented from time to time and as included in the GMP Agreement.

1.8      The term Substance shall mean mirtazapine.

                                       2
<PAGE>   3
                                                                   EXHIBIT 10.27

1.9      The term "Requirements" shall mean all quantities of the Product to be
         used by Organon, its Affiliated Companies or sublicensee(s) for
         clinical trial materials and for distribution, marketing and sale of
         the Product and samples thereof during the term of this Agreement.

1.10     The term "Self-Supply" shall mean the manufacture of the Product by
         Organon or its Affiliated Companies or third parties as permitted by
         Sections 2.3 and 2.4 hereof.

1.11     Third Party Manufacturer -- Third Party Manufacturer shall mean a
         manufacturer familiar with and capable of producing product using
         Orasolv(R) and PakSolv(TM) technologies. Any Third Party Manufacturer
         chosen by the Manufacturer must be approved by Organon which approval
         will not be unreasonably withheld.

1.12     "Coated Substance" shall mean mirtazapine coated as per the NDA
         [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**] for Remeron(R)and any
         supplements and amendments thereto.

1.13     Production Yield: Let Output Y be, the amount of blistered Product made
         expressed in kg of [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
         FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**]
         Substance.

         Let Input X be, the amount of [**CONFIDENTIAL TREATMENT REQUESTED,
         PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
         COMMISSION.**] Substance, as delivered by Organon, expressed in kg used
         to produce Output Y.

         Production Yield will be defined as (Output Y divided by Input X)
         multiplied by 100%.

Section 2:  APPOINTMENT

2.1      Organon herewith appoints Manufacturer to perform the manufacture of
         the Product, in accordance with the Specifications and with the use of
         the Substance in accordance with the terms of this Agreement, on behalf
         of Organon and Manufacturer accepts this appointment. Manufacturer may,
         with Organon's approval, have the Product manufactured by an Affiliated
         Company of the Manufacturer.

                                      3
<PAGE>   4
                                                                   EXHIBIT 10.27

2.2      For a period of five years commencing from January 15, 2001 and upon
         the terms and conditions contained herein, Organon will purchase all of
         its Requirements of the Product exclusively from the Manufacturer and
         the Manufacturer will sell and deliver to Organon F.O.B. Origin,
         Freight Collect, Organon's Requirements of the Product under the terms
         of this Agreement.

2.3      If Manufacturer is unable to supply Organon with Organon's Requirements
         within sixty (60) days of a delivery date, as determined pursuant to
         Section 9.2, for any reason other than Organon's failure to provide
         Substance to Manufacturer according to the lead time in Section 9.4 or
         a condition of force majeure (which will include but is not limited to,
         acts of God, explosion, fire, flood, earthquake or tremor, war whether
         declared or not, civil strife, riots, embargo, losses or shortages of
         power, supply shortages other than Substance, labor stoppages other
         than those of Manufacturer, damage to or loss of Product in transit,
         currency restrictions, or events caused by reason of laws, regulations
         or orders by any government, governmental agency or instrumentality or
         by any other supervening, unforeseeable circumstances whatsoever
         reasonably beyond the control of such party), Manufacturer will be
         considered in material breach and Organon may, in addition to any other
         remedy available to it, elect to Self-Supply, including supply in the
         Americas, without the payments in Sections 2.4 and 2.5, during the
         period that Manufacturer is unable to supply Organon's requirements and
         for such additional time so that such Self-Supply will be an
         economically reasonable endeavor. In the event of force majeure,
         Organon may also elect to Self-Supply under the same conditions and
         terms as for breach. In the event of breach or force majeure,
         Manufacturer agrees, at its own costs and expense in the case of breach
         and at Organon's costs and expense in case of force majeure, to provide
         technical support and assistance to ensure smooth and satisfactory
         establishment of the Orasolv(R) technology at Organon's Self-Supply
         site.

2.4      Organon may also elect to Self Supply at any time after the five (5)
         year period described in Section 2.2 by a minimum of an eighteen (18)
         month notice to Manufacturer. If Organon so elects to Self Supply,
         Manufacturer will provide to Organon, at Organon's sole expense,
         technical support and assistance to ensure the smooth and satisfactory
         establishment of the OraSolv Technology at the new manufacturing site.
         Organon will pay Manufacturer under this section a $[**CONFIDENTIAL
         TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
         SECURITIES AND EXCHANGE COMMISSION.**] technology transfer fee,
         $[**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**]

                                      4
<PAGE>   5
                                                                   EXHIBIT 10.27

         eighteen (18) months after notification and $[**CONFIDENTIAL TREATMENT
         REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND
         EXCHANGE COMMISSION.**] after FDA approval and will promptly reimburse
         Manufacturer for all of its reasonable actual out of pocket expenses
         incurred in support of the technology transfer.

2.5      If Organon elects to Self Supply according to Section 2.4, then there
         will be a good faith negotiation between both parties of an additional
         per tablet payment by Organon and the period of the duration of these
         payments to cover the then value of Manufacturer's capital investments
         to meet the requirements under this Agreement.

2.6      Any Third Party Manufacturer selected by Organon pursuant to Section
         2.3 for Self-Supply, must be approved by Manufacturer and such approval
         will not be unreasonably withheld or delayed. As a condition of
         Manufacturer's approval, Organon shall have the selected third party
         enter into an agreement with Manufacturer with a confidentiality clause
         consistent with Section 4 of the License Agreement referred to in the
         first whereas clause of this agreement.

Section 3:  MANUFACTURING INSTRUCTIONS

3.1      Manufacturer shall perform the manufacture of the Product strictly in
         conformity with the instructions as specified in the GMP Agreement.

3.2      Manufacturer shall make no alterations in the Specifications of the
         Product or to the manufacturing process, without the prior written
         approval of Organon and as provided in the GMP Agreement. Any and all
         process deviations will be documented and reported to Organon.
         Documented evidence of all process deviations will be provided as part
         of manufacturing records to be forwarded to Organon prior to final
         release of Product. Organon shall have sole responsibility for
         determining the marketability of all batches for which a process
         deviation occurred.

Section 4:  QUALITY CONTROL

4.1      Manufacturer shall be responsible for the quality control of the
         Product manufactured by the Manufacturer and shall carry out the tests
         and analysis included in such quality control strictly in conformity
         with the instructions as specified in the GMP Agreement. Organon may
         test the

                                      5
<PAGE>   6
                                                                   EXHIBIT 10.27

         Product after receipt, as Organon deems appropriate. Organon will
         maintain a post-marketing stability program for the Product in
         conformity with the GMP Agreement. Organon may request Manufacturer to
         maintain such post-marketing stability program. If elected to do so,
         Manufacturer and Organon will agree upon a price for such program.

4.2      Manufacturer shall maintain complete and adequate records of all tests
         and analysis carried out in accordance as specified in the GMP
         Agreement and shall deliver a Certificate of Analysis with each batch
         of Product.

4.3      Manufacturer shall keep sealed samples of: each batch of Product, each
         batch of raw material used, and samples of each batch of components
         used for the manufacture of each batch of Product will be retained for
         a minimum of one year past the expiration date of each batch of
         Product, to verify the quality of the pertinent batch of Product at the
         time it was delivered to Organon. All documentation with respect to
         batch of Product, raw material, components and production of Product
         will be retained by Manufacturer a minimum of one year past the
         expiration date of the batch of Product.

4.4      Manufacturer agrees to conduct additional validation activities as
         required by regulatory authorities or at the request of Organon.
         Organon agrees to pay, a mutually agreed upon sum, for Manufacturer to
         perform such validation activities and supply sufficient quantity of
         Substance to complete such validation activities.

4.5      Manufacturer represents and warrants that the Product shall not be
         adulterated or misbranded, and shall be free of all defects of any kind
         whatsoever and to the best of the Manufacturer's knowledge,
         Manufacturer's technology does not infringe in any way whatsoever any
         rights of any third party. MANUFACTURER MAKES NO OTHER WARRANTIES OF
         ANY KIND, EXPRESS OR IMPLIED, AND EXPRESSLY DISCLAIMS ANY WARRANTY OF
         MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND ANY AND ALL
         LIABILITY FOR SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES.

4.6      The GMP Agreement will supplement the terms of this Agreement with
         regard to quality control.

Section 5:  PACKAGING OF THE PRODUCT

                                       6
<PAGE>   7
                                                                   EXHIBIT 10.27

5.1      The Product shall undergo primary packaging and labeling by
         Manufacturer according to Organon's instructions. The current primary
         packaging instructions are included in the GMP Agreement and shall not
         be modified by Organon without the prior written consent of
         Manufacturer, which consent shall not be unreasonably withheld or
         delayed. Approved blister artwork shall be provided to the Manufacturer
         by Organon at least forty-five (45) days prior to the delivery date for
         that shipment of Product specified in the applicable purchase order.

5.2      Country specific labeling may be required. The text appearing on
         primary packing and labeling of the Product shall be as determined by
         Organon subject to Manufacturer's prior written approval, which shall
         not be unreasonably withheld or delayed. Manufacturer and Organon agree
         to no more than [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
         FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**]
         variants required per batch of Product, unless previously agreed. A
         premium, which, if needed, will be $[**CONFIDENTIAL TREATMENT
         REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND
         EXCHANGE COMMISSION.**] for batches of Product with blistering variants
         which exceed [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
         SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**]. The text
         shall be as specified in the packaging instructions. Organon shall
         ensure that all packaging for the Product complies with applicable laws
         and regulations in each country in which it will be sold.

5.3      Organon will reimburse Manufacturer for reasonable costs incurred by
         Manufacturer in making changes to its packaging line required to
         manufacture the Product as mandated by regulatory revisions or as
         required by Organon. This will include, but not be limited to, plate
         and die charges due to label changes and Product identification
         requirements, and for any packaging components rendered obsolete by the
         changes.

Section 6:  REJECTIONS AND YIELD

6.1      Within forty-five (45) days after delivery of each of the batches of
         the Product Organon shall inform Manufacturer of any obvious
         non-conformance of the delivered batches with the specifications and/or
         significant deviations from cGMP's. Within forty five (45) days after
         such notification, and in the event it appears that such a
         specification and/or cGMP non-conformance is due to faulty manufacture,
         release, primary packaging or labeling of the relevant batch(es) of the
         Product, which fact

                                       7
<PAGE>   8
                                                                   EXHIBIT 10.27

         shall be established on the basis of the corresponding sealed samples
         retained by Manufacturer, utilizing an outside independent laboratory
         if necessary, the cost of which is borne by the party found at fault
         and whose findings shall be binding, or based on the process deviation
         documentation provided to Organon, the Manufacturer shall replace such
         batches free of charge. In the event Organon does not notify
         Manufacturer of any such obvious non-conformance within said period,
         the relevant batches shall be deemed to be in conformance with the
         Specifications, except for non-obvious defects or non-conformance
         relating to the manufacturing or testing of Product by Manufacturer,
         and Manufacturer shall have no further obligations and liabilities
         towards Organon with regard to those batches.

6.2      If found at fault, Manufacturer's liability, to Organon, for defective
         or non-conforming Product shall be replacement of the Product,
         exclusive of the cost of the Substance. For Substance lost through
         mishandling or negligence (non-batch processing related) Manufacturer
         shall promptly reimburse Organon, at the rate of $[**CONFIDENTIAL
         TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
         SECURITIES AND EXCHANGE COMMISSION.**] per gm. In the case of defective
         or non-conforming Product, Manufacturer shall replace Product at its
         cost within sixty (60) days of notification of the findings. In no
         event shall Manufacturer be liable for any indirect or consequential
         damages in connection with any non-conforming batch of Product. Annual
         increases to the rate of reimbursement of Substance will commence on
         January 1, 2002 and are to be established January of each calendar year
         thereafter. [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
         SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**].

6.3      In 2001, Manufacturer will complete the validation batches for Remeron
         SolTab using [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
         SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**] pursuant to
         sufficient supply of [**CONFIDENTIAL TREATMENT REQUESTED, PORTION
         OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
         COMMISSION.**] from Organon. Thereafter, but subject to FDA approval if
         needed, all future production of Product will be produced using the
         process with the [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
         FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**]. After
         twenty-five (25) batches of coated Substance are manufactured,
         Manufacturer and Organon will agree upon a minimum Production Yield. If
         the average of the Production Yield of the batches of Product produced
         by Manufacturer during a calendar year is less than the minimum
         Production Yield,

                                       8
<PAGE>   9
                                                                   EXHIBIT 10.27

         Manufacturer will pay to Organon by January 31 of the subsequent year
         the amount equal to the difference between the amount of Substance
         required to make the number of batches of products in that calendar
         year using the minimum Production Yield and the amount of Substance
         used for such batches using the actual Production Yield times
         [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**] according to Section
         6.2.

Section 7:  RECALLS

7.1      If Organon is required (or voluntarily decides) to initiate a recall,
         product withdrawal or field correction of any Product manufactured by
         Manufacturer under this Agreement, whether or not such recall has been
         requested or ordered by any governmental agency, Organon will notify
         Manufacturer's President or Chief Operating Officer, and Manufacturer
         shall fully cooperate with Organon. If Manufacturer believes that a
         recall, product withdrawal, or field correction by Organon may be
         necessary or appropriate, Manufacturer will notify Organon of its
         beliefs, and after Organon's decision the parties will cooperate in
         promptly implementing Organon's decision.

7.2      With respect to any recall, product withdrawal, or field correction,
         Organon will make all contacts with the FDA and any foreign regulatory
         agencies and will be responsible for coordinating all of the necessary
         activities in connection with such recall, product withdrawal, or field
         correction, and shall make any statements to the media, including, but
         not limited to, press releases and interviews for publication or
         broadcast.

7.3      If any recall, product withdrawal, or field correction is initiated
         solely because of non conformance or a defect in any Product arising
         from the manufacture, processing, primary packaging or holding of the
         Product by Manufacturer, Manufacturer will (i) replace all defective
         Product free of charge, (ii) reimburse Organon for out-of-pocket costs
         actually paid by Organon to third parties for transportation, secondary
         packaging and destruction of the recalled Product, and (iii) reimburse
         Organon for its out of pocket administrative expenses incurred in
         implementing the recall. Manufacturer shall provide, within a
         reasonable amount of time, a full replacement of the recalled Product
         due to recall, product withdrawal or field correction. The maximum time
         for Manufacturer to provide full replacement will be sixty (60) days
         except for Product covered by a pending investigation or subject to a
         condition of force majeure.

                                       9
<PAGE>   10
                                                                   EXHIBIT 10.27

7.4      If any recall, product withdrawal or field correction is required due
         to reasons other than those specified in Section 7.3, i.e., defective
         materials supplied by Organon or improper handling of Product by
         Organon, the costs of such recall, including the costs of any of
         Manufacturer's work in process affected by the recall, will be borne by
         Organon.

Section 8:  MATERIALS

8.1      Except for Substance, the materials and components for the manufacture
         of the Product, as well as the primary packaging materials shall be
         purchased by Manufacturer for its own account and responsibility. All
         such materials and components shall be in conformity with any quality
         requirements included in the GMP Agreement.

8.2      All vendors or suppliers used by the Manufacturer shall be approved
         through the Manufacturer's internal certification program. Manufacturer
         shall send a certificate of conformance to Organon certifying each
         vendor's compliance with cGMP's or other appropriate quality standards
         on an annual basis or upon Organon's request.

8.3      Organon shall supply to Manufacturer the required amounts of Substance
         free of charge, which shall only be used to manufacture Product for
         Organon, according to the delivery schedule described in Section 9. The
         Substance supplied by Organon hereunder shall conform to the
         Specifications contained in the GMP Agreement and shall be accompanied
         by a suitable Certificate of Analysis. While under the control of
         Manufacturer, Substance remains the property of Organon. Within 5
         working days of month end Manufacturer will provide Organon with the
         following:

         a.   A list of the balance of Substance and Substance related inventory
              at CIMA Labs at month end by lot. This list will include the
              Substance in raw material form reported in grams by lot number.
              Work in Process ("WIP") or Finished Goods which include Substance
              will be reported in the appropriate unit of measure for each WIP
              or Finished Goods level, i.e.: grams, tablets or strips, by WIP or
              Finished Goods lot number.

         b.   Inventory records for all Substance and Substance related
              inventory. These records will include, for each lot at each
              manufacturing stage, a beginning balance, plus or minus all
              increases or decreases to the lot with adequate descriptions or
              explanations, and the balance of the lot at month end.

         The above requirements can be changed if mutually agreed upon.

                                       10
<PAGE>   11
                                                                   EXHIBIT 10.27

         Any non-batch processing related loss of Substance, while under the
         control of the Manufacturer, which has been determined to be the fault
         of the Manufacturer, will result in reimbursement by Manufacturer to
         Organon in the terms described in Section 6.2. Organon will provide to
         Manufacturer a Certificate of Insurance covering the Substance while it
         is in the control of the Manufacturer.

8.4      Manufacturer shall inspect and test the materials, components and
         Substance before processing in order to verify their conformity with
         the requirements included in the GMP Agreement.

8.5      Organon shall reimburse Manufacturer for all materials and components
         as well as primary packaging materials purchased specifically for the
         manufacture of the Product that can not be used to manufacture the
         Product due to reductions in Organon's purchase orders or due to
         changes to the manufacturing process or primary packaging art work
         mandated by regulatory authorities or Organon, or due to Organon's
         decision to Self-Supply for reason other than Manufacturer's material
         breach. In no event will Organon be responsible for more than 6 (six)
         months' worth of inventory based on the current forecast at the time of
         the changes within the limits stated within Section 9.1.

8.6      Organon and its representatives shall have the right to inspect and
         audit Manufacturer's book, records and inventories relating to Product
         during regular business hours, giving at least forty-eight (48) hours
         prior notice.

Section 9:  FORECAST, ORDERS AND DELIVERY

9.1      Before the tenth (10th) day of each calendar quarter, Organon shall
         provide Manufacturer with a written 12 month rolling forecast of its
         Requirements of Product and Samples and shall update such forecasts on
         a quarterly basis or more frequently. Organon will place firm orders
         with a minimum of a ninety (90) day lead-time before delivery is
         required. Along with this forecast Organon, will communicate in Q1 and
         Q4 of each year a Long Range Plan (LRP), which will indicate Organon's
         Products needs over a maximum period of 2 years. The LRP is not a
         commitment for future purchase orders.

9.2      Each Organon purchase order for Product will be considered accepted by
         Manufacturer and Product will be delivered according to the times and
         location in that purchase order if such purchase order is in accordance

                                       11
<PAGE>   12
                                                                   EXHIBIT 10.27

         with this Section. Manufacturer reserves the right to reject any
         purchase order for Product in which the first delivery date for Product
         is substantially earlier than 90 days from the date Manufacturer
         received that purchase order. Organon has the right to reconfirm orders
         in writing, up to forty-five (45) days before the delivery date
         specified on the purchase order, to issue change orders to increase the
         quantity of Product ordered on a initial purchase order(s) by up to
         [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**] of stated tablet
         requirement or decrease the quantity of Product ordered on the initial
         purchase order(s) by up to [**CONFIDENTIAL TREATMENT REQUESTED, PORTION
         OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**
         ] of stated tablet requirements. In the event Organon decreases by more
         than [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
         SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**] the quantity
         of Product requested on a purchase order(s) during the period
         commencing on the date of receipt of that purchase order by
         Manufacturer up to forty-five (45) days of the delivery date for that
         shipment specified on such purchase order or decreases by any amount
         the quantity of Product ordered within forty-five (45) days of the
         delivery date specified on such purchase order(s), Organon shall pay
         Manufacturer within 30 days of the Manufacturer's invoice date a
         Cancellation Fee equal to [**CONFIDENTIAL TREATMENT REQUESTED, PORTION
         OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
         COMMISSION.**].

         Manufacturer agrees to commit an annual manufacturing capacity of
         [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**] for the manufacture of
         the Product ("AMC"). As from 2002, if Organon fails to utilize a
         minimum of [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
         SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**] of the AMC
         ([**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**]) in a given year then a
         new lower AMC will be agreed to by the parties for future years.

         Manufacturer's available production capacity (APC) is projected to be
         [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**] in 2002 and
         [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**] in 2003. The APC will
         be mutually agreed to by both parties for years 2004 and beyond;
         provided, however, the APC for any

                                       12

<PAGE>   13
                                                                   EXHIBIT 10.27

         year will not be less than the previous year's (AMC plus RAMC) unless
         Organon wishes to lower such amount.

         Organon may, based on its LRP, reserve additional manufacturing
         capacity beyond the AMC up to the Manufacturer's APC for that year
         [herein called "(RAMC)"].

         In the event Organon does not order an amount of Product for delivery
         in a calendar year which is at least [**CONFIDENTIAL TREATMENT
         REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND
         EXCHANGE COMMISSION.**] of the RAMC established by Organon for that
         calendar year, Organon shall pay the Manufacturer within 30 days of the
         Manufacturer's invoice date a Capacity Reservation Fee, which is equal
         to $[**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
         SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**] times
         [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**] of the difference
         between the RAMC and the actual amount of Product ordered for delivery
         in such calendar year by Organon. Organon has the right to increase or
         decrease the RAMC for a calendar year without any penalty or fee
         whatsoever, provided the change is communicated to the manufacturer no
         later than December 1 of the calendar year immediately preceding the
         calendar year to which a Capacity Reservation Fee would apply.

         Organon agrees to be held liable for all obsolesce, for no more than 6
         months worth of inventory, pursuant to Section 8.5, of materials
         resulting from changes in Product or changes in purchase order
         requirements.

9.3      Quantities of Product shall be delivered to Organon or an Affiliated
         Company of Organon designated by Organon, F.O.B. Origin Freight Collect
         (latest edition of the Incoterms) and risk of loss shall pass at the
         time of such delivery.

9.4      Before the twentieth (20th) day of each calendar quarter, Manufacturer
         shall provide Organon with written rolling-forecasts of its
         requirements of Substance for each of the twelve (12) forthcoming
         calendar months and shall update such forecasts on a quarterly basis.
         The Substance shall be delivered by Organon to Manufacturer, sixty (60)
         days prior to the delivery date for that shipment of Product on that
         purchase order. If Organon fails to deliver Substance sixty days prior
         to such delivery date the parties will agree to a new purchase order
         delivery date.

                                       13

<PAGE>   14
                                                                   EXHIBIT 10.27

9.5      After January 15, 2001, unless otherwise mutually agreed, if
         Manufacturer delivers Product twenty (20) business days after or ten
         (10) business days before the specified delivery date Manufacturer
         shall pay to Organon a penalty of [**CONFIDENTIAL TREATMENT REQUESTED,
         PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
         COMMISSION.**] of the value of Product for that delivery per business
         day for each business day that such order is late or early, not
         including any Product covered by a pending investigation or subject to
         a condition of force majeure. Any such penalty shall not exceed
         [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.**] percent of the value of
         Organon's Purchase Order.

9.6      If Organon fails to deliver Substance in sufficient quantities for the
         Manufacturer to maintain safety stock as describe in Section 9.4 in
         time for the Manufacturer to meet delivery times of accepted purchase
         orders, this shall result, to Organon, in a penalty of $[**CONFIDENTIAL
         TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
         SECURITIES AND EXCHANGE COMMISSION.**] for the number of tablets
         specified for that delivery in that purchase order; provided, however,
         that any such penalty will only be due and payable in the event
         Manufacturer can prove that this resulted in idle time of allocated
         machine capacity for such delivery in that purchase order by failure of
         Organon to deliver Substance. Such idle time of allocated machine
         capacity means the machine availability was not used for e.g., required
         maintenance or other production orders. This Section will only be in
         effect when both Organon and the Manufacturer have agreed on a minimum
         Production Yield factor as mentioned in Section 6.3.

Section 10:  PRICES AND PAYMENTS

10.1     As a consideration for the manufacture of the Product by Manufacturer,
         Organon shall pay to Manufacturer the purchase prices as specified in
         Exhibit I attached hereto. Annual price increases will commence on
         January 1, 2002, and are to be established January of each calendar
         year thereafter. Any price increases will be mutually agreed upon by
         both the Manufacturer and Organon [**CONFIDENTIAL TREATMENT REQUESTED,
         PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
         COMMISSION.**]

10.2     All invoices for delivery of the Product shall be paid by Organon in
         US$ within thirty (30) days after the date of the invoice. The date of
         the

                                       14
<PAGE>   15
                                                                   EXHIBIT 10.27

         invoice shall not precede the Manufacturer's release of the Product.
         Each invoice shall be accompanied with a Certificate of Analysis for
         the Coated Substance and a Certificate of Conformance for the blistered
         Product for each batch of Product included in the invoice. There will
         be a [**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
         SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**], of invoice
         price, penalty per month, for each month a payment is past due. Such
         penalty shall not exceed [**CONFIDENTIAL TREATMENT REQUESTED, PORTION
         OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
         COMMISSION.**] per annum.

Section 11:  INSPECTION

11.1     Manufacturer shall keep such books and records regarding the
         manufacture and quality control of the Product in accordance with the
         instructions included in the Manufacturing Instructions, QC
         Instructions as defined in the Good Manufacturing Practices (GMP)
         Agreement and/or in compliance with 21CFR 211. With at least
         forty-eight (48) hours notice Organon shall have the right to inspect
         such books and records at any time during regular business hours.

11.2     Organon shall have the right to inspect Manufacturer's facilities to
         see if Manufacturer is in compliance with the Manufacturing
         Instructions, the QC Instructions as defined in the GMP Agreement and
         cGMP's. Any representatives of Organon designated for this purpose
         shall have the right to inspect the manufacturing and quality control
         facilities and warehouses of Manufacturer during regular business
         hours, giving at least forty-eight (48) hours prior notice.

Section 12:  ADDITIONAL RESPONSIBILITIES OF MANUFACTURER

12.1     Manufacturer shall forward to Organon all inquiries from any person
         concerning the Product within fifteen (15) business days after
         Manufacturer receives each such inquiry, and provide Organon with any
         reasonable assistance requested in connection with customer complaints
         relating to the Product. This assistance shall include inspection of
         retains, review of appropriate test records, testing of samples and
         issuance of formal reports summarizing complaint investigations.

                                       15
<PAGE>   16
                                                                   EXHIBIT 10.27

12.2     Manufacturer shall inform Organon of any defective Product,
         manufacturing process deviation or information of which Manufacturer is
         aware that suggests that a defect may exist, within five (5) business
         days after becoming aware of any such defective Product or deviation
         information.

12.3     Manufacturer shall inform Organon of any pending or threatened
         litigation, governmental investigation, proceeding or action involving
         the Product or Manufacturer's manufacturing or other facilities for the
         Product, within five (5) business days after receiving notice thereof.

12.4     Manufacturer shall inform Organon within forty-eight (48) hours of any
         FDA general GMP inspection or other FDA inspection involving the
         Product. The Manufacturer will provide Organon with a copy of the form
         483, or any other pertinent governmental agency form or document, as
         well as the Manufacturer's response thereto within Forty-eight (48)
         hours after Manufacturer's receipt of such form or document or
         response. Manufacturer may redact any confidential information of third
         parties from such documents.

12.5     Manufacturer shall supply an Annual Product Review, as required by
         21CFR 211.180(e), no more than 30 days following each sNDA anniversary
         date throughout the life of this Agreement.

Section 13:  ADDITIONAL RESPONSIBILITIES OF ORGANON

13.1     Organon shall forward to Manufacturer copies of any complaints it
         receives from customers concerning the Product for which Manufacturer's
         assistance is requested, within fifteen (15) business days after
         receiving any such complaint.

13.2     Organon shall inform Manufacturer of any defective Product or of
         information that suggests that a defect may exist within five (5)
         business days after becoming aware of such defective Product or
         information.

13.3     Organon shall inform Manufacturer of any pending or threatened
         litigation or governmental investigation involving the manufacture of
         the Product within five (5) business days after Organon receives notice
         thereof.

13.4     Organon shall comply with applicable laws and governmental regulations
         affecting the sale and distribution of the Product.

                                       16
<PAGE>   17
                                                                   EXHIBIT 10.27

13.5     Organon shall inform Manufacturer (and provide copies when available)
         of regulations and requirements of applicable foreign country
         regulatory authorities with respect to the Product ordered by Organon
         for sale in a foreign country.

Section 14:  INDEMNIFICATION

14.1     Manufacturer will indemnify and hold Organon and Organon's Affiliated
         Companies harmless from and against all claims, suits and proceedings,
         and all damages, losses, costs, recoveries and expenses, including
         reasonable legal expenses and costs (including attorneys' fees) that
         Organon or Organon's Affiliated Companies may incur, arising out of any
         third party's claim of property damage or personal injury or death
         arising from Manufacturer's negligent or willful misconduct in its
         performance of this Agreement, any non-conformance or defective Product
         relating to the manufacturing or testing of Product by Manufacturer or
         any breach of a representation or warranty given herein by
         Manufacturer. However, Manufacturer will in no event be liable for any
         such claims, damages, losses, costs or expenses to the extent they
         arise out of or result from materials, including the Substance,
         supplied by Organon to Manufacturer, or from Organon's or Organon's
         Affiliated Companies' negligence or willful misconduct.

14.2     Organon will indemnify and hold Manufacturer and Manufacturer's
         Affiliated Companies harmless from and against all claims, suits and
         proceedings, and all damages, losses, costs, recoveries and expenses,
         including reasonable legal expenses and costs (including attorneys'
         fees) that Manufacturer or Manufacture's Affiliated Companies may
         incur, arising out of any third party's claim of property damage or
         personal injury or death arising from materials, including the
         Substance, supplied by Organon to Manufacturer or from Organon's or
         Organon's Affiliated Companies' negligent or willful misconduct in its
         performance of this Agreement or any breach of a representation or
         warranty given herein by Organon or from the sale or use of Product
         except to the extent Manufacturer is responsible to indemnify Organon
         under Section 14.1 with respect thereto. However, Organon will in no
         event be liable for any such claims, damages, losses, costs or expenses
         to the extent they arise out of or result from materials supplied by
         Manufacturer to Organon, or from Manufacturer or Manufacturer's
         Affiliated Companies' negligence or willful misconduct.

                                       17
<PAGE>   18
                                                                   EXHIBIT 10.27

14.3     In the event any third party asserts a claim covered by Sections 14.1
         or 14.2, the indemnified party will give prompt notice to the
         indemnifying party, who may, at its election, handle and control the
         defense or settlement of the claim at its own expense by giving prompt
         notice to the indemnified party. However, the indemnifying party will
         not settle any such claim without the indemnified party's prior written
         consent, which will not be unreasonably withheld. If the indemnifying
         party does not give such notice and does not proceed diligently to
         defend the claim within thirty (30) days after receipt of notice, the
         indemnifying party will be bound by any defense or settlement that the
         indemnified party may make as to that claim and will reimburse the
         indemnified party for any expenses related to the defense or settlement
         of the claim. The parties will cooperate in defending against any
         asserted third-party claims. Indemnification of the indemnified party
         will also cover the indemnified party's directors, officers, employees,
         agents, Affiliated Companies, and third parties performing services for
         the indemnified party.

Section 15:  CONFIDENTIALITY

15.1     It is understood and agreed by Manufacturer, that any and all
         information and data disclosed by Organon to Manufacturer under this
         Agreement is and shall remain the exclusive property of Organon. It is
         acknowledged by Manufacturer that the information and data are only
         disclosed to Manufacturer for the purposes and use described in this
         Agreement and that they are to be regarded as trade secrets containing
         unpublished results of private research and experience which are used
         in Organon's business and which are of a nature customarily held in
         strict confidence and regarded as privileged knowledge; consequently,
         any other use or any disclosure by Manufacturer of information and data
         in violation of this Section 15.1 may harm and damage Organon's
         legitimate business interests. Manufacturer hereby undertakes to keep
         secret and confidential the above-mentioned information and data during
         the term of this Agreement as well as thereafter and not to use or
         disclose the information and data to any third party, person, or
         government institution without Organon's prior written approval and not
         to use it for any other use or purpose than those described in this
         Agreement.

15.2     The obligations described in Section 15.1 above shall not be applicable
         to any part of the information and data disclosed by Organon under this
         Agreement which:

         -  at the moment of disclosure is general (public) knowledge;
         -  after disclosure, through no fault of Manufacturer, becomes

                                       18
<PAGE>   19
                                                                   EXHIBIT 10.27

            general (public) knowledge;

         -  properly and lawfully becomes available to Manufacturer, from the
            source not bound to Organon by a secrecy obligation and provided
            this can be adequately substantiated;

         -  is required to be disclosed under the Securities Act of 1933, as
            amended, or the Securities Exchange Act of 1934, as amended, or
            which is otherwise required by law to be disclosed.

15.3     Upon termination or expiration of this Agreement Manufacturer hereby
         undertakes, upon such request from Organon, to promptly return all
         information and data on any and all media received from Organon and not
         to retain any copy or photocopy of such information and data and to
         stop any further use of Organon's information and data as referred to
         in Section 15.1 above.

15.4     The terms of Section 4 of the License Agreement shall apply to the know
         how, information and data disclosed by Manufacturer to Organon under
         this Agreement.

Section 16:  TERM AND TERMINATION

16.1     This Agreement shall be effective for a term of five years from the
         date specified in Section 2.2 and shall automatically renew for
         successive three year periods, unless Organon notifies Manufacturer
         that it will terminate this agreement or any renewal thereof within at
         least 18 months prior to the end of the current term or unless
         terminated under Section 16.2. For each renewal period, the parties
         agree to negotiate in good faith any increase or decrease of the prices
         for Product for such renewal period.

16.2     Notwithstanding the preceding paragraph, this Agreement may be
         terminated forthwith by registered mail or overnight courier:

         a) by either Party in the event the other Party shall materially breach
         any of its obligations under this Agreement and shall fail to remedy
         such breach within sixty (60) days from receipt of written notice of
         such breach by the Party not in default; or

         b) by either Party in the event of the other Party's liquidation,
         bankruptcy or state of insolvency; or

         c) by Organon in the event Manufacturer without the written consent of
         Organon assigns this Agreement in whole or in part to any third party
         (not

                                       19
<PAGE>   20
                                                                   EXHIBIT 10.27

         as provided for in Section 18.3) or if the majority of the shares of
         Manufacturer are acquired by a current or future competitor of Organon
         in the antidepressant market.

         If either clause b or c occurs, Organon shall have the right to Self
         Supply without payments set forth in Sections 2.4 and 2.5.

Section 17:  APPLICABLE LAW AND DISPUTE RESOLUTION

17.1     The validity, construction and performance of this Agreement shall be
         governed by and construed in accordance with the laws of the state of
         Delaware and the federal law of the United States of America.

17.2     The Parties shall attempt in good faith to resolve promptly any dispute
         arising out of or relating to this Agreement by negotiation. If the
         matter can not be resolved in the normal course of business any
         interested Party shall give the other Party written notice of any such
         dispute not resolved, after which the dispute shall be referred to more
         senior executives of both Parties, who shall likewise attempt to
         resolve the dispute.

17.3     If any dispute has not been resolved by non-binding means as provided
         in Section 17.2 above within forty-five (45) days of the initiation of
         such procedure, the dispute shall be finally and exclusively settled by
         arbitration by three (3) independent arbitors in Minneapolis, Minnesota
         under the Uncitral Arbitration Rules. Each party shall appoint one (1)
         arbitrator, and those two (2) arbitrators shall appoint a third by
         mutual agreement and in accordance with the Uncitral Arbitration Rules.
         The appointing authority shall be the London Court of International
         Arbitration in London, England. The language of the arbitration shall
         be English. The arbitration shall be in lieu of any other remedy and
         the award shall be final, binding and enforceable by any court having
         jurisdiction for that purpose. The Parties further agree that the
         arbitrators are not authorized to award punitive damages in connection
         with any controversy or claim settled by arbitration.

17.4     This Section shall, however, not be construed to limit or to preclude
         either Party from bringing any action in any court of competent
         jurisdiction for injunctive or other provisional relief as necessary or
         appropriate.

Section 18:  MISCELLANEOUS

                                       20
<PAGE>   21
                                                                   EXHIBIT 10.27

18.1     Headings. All headings of this Agreement are added for the purpose of
         convenience only and the contents and meaning of such headings shall in
         no way limit the meaning and applicability of the relevant Sections.

18.2     Entire Agreement. This Agreement, the License Agreement and the GMP
         Agreement constitutes the entire agreement between the Parties and
         annuls and replaces any other agreement or understanding whether
         written or oral which may have existed between the Parties with respect
         to the subject matter hereof. All Exhibits attached hereto form an
         integral part of this Agreement. This Agreement can be modified or
         amended and rights under this Agreement waived only in writing signed
         by the Party to be charged.

18.3     No Assignment. Manufacturer shall not assign or otherwise transfer this
         Agreement or any part thereof to any third party, without the written
         consent of Organon, which will not be unreasonably withheld or delayed.
         Organon may assign this Agreement to an affiliate without
         Manufacturer's consent or to a third party with Manufacturer's consent,
         which will not be unreasonable withheld or delayed.

18.4     Binding upon Successors. This Agreement shall bind and benefit the
         Parties and their respective successors and permitted assigns.

18.5     Notices. All notices in connection with this Agreement shall be in
         writing and be in the English language (as shall all other written
         communications and correspondence) and may be given by personal
         delivery, prepaid registered airmail letter, telegram or telefax,
         addressed to the Party required or entitled to receive same at its
         address set forth below, or to such other address as it shall later
         designate by like notice to the other Party. Notice of termination of
         this Agreement if given by telegram or telefax, shall be confirmed by
         prepaid registered airmail letter dated and posted the same day. The
         effective date of any notice if served by telegram, telex or telefax
         shall be deemed the first business day in the city of destination
         following the dispatch thereof and if given by prepaid registered
         airmail letter only, it shall unless earlier received, be deemed served
         not later than seven (7) days after date of posting.

Notice to Organon shall be to:

Organon Inc.
375 Mt. Pleasant Avenue
West Orange, New Jersey 07052

                                       21
<PAGE>   22
                                                                   EXHIBIT 10.27

Attention: Vice President, Production

with a copy to:

Vice President & General Counsel
Organon Inc.
375 Mt. Pleasant Ave.
West Orange, New Jersey 07052

Notice to Manufacturer shall be to:
CIMA Labs Inc.
Telefax:  1-612-947-8770
Attention: President and Chief Operating Officer

18.6     Severability. All stipulations contained in this Agreement shall be so
         construed as not to infringe any provision of any law prevailing to
         this Agreement. To the extent that, and only to the extent that, any
         stipulation does infringe any such provisions, said stipulation shall
         be deemed void and shall be replaced by a stipulation in such a way as
         in accordance with the prevailing law is possible and in such a way as
         will be the least prejudicable to the interest of either Party. The
         infringement of any provision by a stipulation shall not affect the
         validity of any other stipulation of this Agreement.

18.7     Independent Contractors. The Parties are independent contractors and
         nothing in this Agreement shall imply any principal or agent
         relationship or other joint relationship and neither Party shall have
         the power or authority, either express or implied, to obligate the
         other Party.

18.8     Language. This Agreement is written in the English language and
         executed in two (2) counterparts, each of which shall be deemed an
         original. The English language text of this Agreement shall prevail
         over any translation thereof.

18.9     No Waiver. Failure of either party to insist upon the strict and
         punctual performance of any provision of this Agreement shall not
         constitute a waiver of, or estoppel against asserting the right to
         require such performance, nor should a waiver or estoppel in one case
         constitute a waiver or estoppel with respect to a later breach whether
         of similar nature or otherwise.

                                       22

<PAGE>   23
                                                                   EXHIBIT 10.27

18.10    Back-up Facility. Manufacturer represents and warrants that it will
         have a back-up manufacturing facility [**CONFIDENTIAL TREATMENT
         REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND
         EXCHANGE COMMISSION.**] from [**CONFIDENTIAL TREATMENT REQUESTED,
         PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
         COMMISSION.**]. As soon as the manufacturing facility is operational,
         Organon and Manufacturer will establish the Product, subject to FDA
         SUPAC Guidelines, at the back-up facility. Once the Product is
         established at the back-up facility, pending regulatory approval, the
         back-up facility will be available immediately for production of
         Product including where the manufacturing of Product is for practical
         reasons of any kind no longer possible in the facility that is normally
         used to manufacture Product. The back-up manufacturing facility may be
         located at a Third Party Manufacturer's facility or facilities,
         provided Manufacturer obtains Organon's prior written approval, such
         approval will not be unreasonably withheld or delayed. As mutually
         agreed, Organon will pay Manufacturer for regulatory, development,
         clinical, stability and validation expenses required to establish a
         back-up facility or facilities. The Product will be transferred to the
         back-up facility or facilities under the FDA SUPAC Guidelines, as a
         Level 3 Change.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
in duplicate by their duly authorized representatives to be effective as of the
date first written above

<TABLE>

ORGANON INC.                                              CIMA LABS INC.
<S>                                                       <C>

By:/s/ Patrick J. Osinski                                 By: /s/ John M. Siebert
   ----------------------------------------------             --------------------------------------------
Name: Patrick J. Osinski                                  Name: John M. Siebert
     --------------------------------------------               ------------------------------------------

Title: Vice President                                     Title: President and CEO
      -------------------------------------------               ------------------------------------------

By:/s/ Dante Serricchio                                   By:/s/ John Hontz
   ----------------------------------------------            ---------------------------------------------
Name: Dante Serricchio                                    Name: John Hontz
     --------------------------------------------              -------------------------------------------

Title: Vice President                                     Title: Chief Operation Officer
      -------------------------------------------               ------------------------------------------

</TABLE>

                                       23

<PAGE>   24
                                                                   EXHIBIT 10.27

<TABLE>
<CAPTION>

                                                                          Purchase Price per SolTab(TM)
                                                                    ------------------------------------------
CUMULATIVE PURCHASES* OF PRODUCT PER YEAR                           #### mg          #### mg           #### mg
----------------------------------------------------------          -------          -------           -------
<S>                                                                 <C>              <C>               <C>
[**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED           $####            $####             $####
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**]
[**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED           $####            $####             $####
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**]
[**CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED           $####            $####             $####
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.**]
</TABLE>

For each calendar year the initial forecast for that year will be used for
pricing Product invoiced in that year. At the end of each calendar year if the
actual Product purchases are different than such initial forecast and such
actual purchases of Product fall in a higher or lower pricing level, the
difference will be calculated and the Manufacturer or Organon shall pay that
amount to the other Party as the case may be. Notwithstanding the foregoing, no
adjustment will be made if during that year there was an event of material
breach by the Manufacturer or of force majeure.

* Purchases for purposes of this exhibit mean Product invoiced by Manufacturer
during the applicable calendar year.

  #### = [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
         SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***]

                                       24<PAGE>   1
                                                                   EXHIBIT 10.13

                      EIGHTH AMENDMENT TO CREDIT AGREEMENT

         This Amendment ("Amendment") is made as of the 15th day of February,
2001, by and between Electronic Tele-Communications, Inc. (the "Borrower") and
Bank One, Wisconsin (the "Lender").

         WHEREAS, the Borrower and the Lender entered into a Credit Agreement
dated May 17, 1989, as amended (if applicable) (the "Credit Agreement"); and

         WHEREAS, the parties hereto desire to amend the Credit Agreement as set
forth below:

         NOW, THEREFORE, the parties hereto agree as follows:

         1.  Capitalized terms not defined herein shall have the meaning
ascribed in the Credit Agreement.

         2.  The Credit Agreement is hereby amended as follows:

                  2.1 Section 6.8, the Section bearing the heading Consolidated
         Tangible Net Worth of the Credit Agreement, is hereby amended and
         restated in its entirety to read as follows:

                     Permit Consolidated Net Worth at any time during the
         following periods to be less than the following amounts:

<TABLE>
<CAPTION>
                         Period                                   Amount
                         ------                                   ------
             <S>                                                 <C>

             at January 1, 2001 and until June 29, 2001          $4,400,000.00
             at June 30, 2001 and until September 29, 2001       $4,500,000.00
             at September 30, 2001 and until December 30, 2001   $4,600,000.00
             at December 31, 2001 and thereafter                 $4,700,000.00

</TABLE>

                  2.2 Section 5.2, the Section bearing the heading Periodic
         Financial Statements of the Credit Agreement, is hereby amended and
         restated in its entirety to read as follows:

             Furnish to the Bank within 20 days after the end of each month
         ETC's balance sheet of income and retained earnings for the period then
         ended. All financial reports required to be provided under this Credit
         Agreement shall be prepared in accordance with generally accepted
         accounting principals, applied on a consistent basis and certified by
         the Borrower as being true and correct.

         3.  The Borrower represents and warrants that (a) the representations
and warranties contained in the Credit Agreement are true and correct in all
material respects as of the date of this Amendment, (b) no condition, act or
event which could constitute an Event of Default under the Credit Agreement
exists, and (c) no condition, event, act or omission has occurred, which, with
the giving of notice or passage of time, would constitute an Event of Default
under the Credit Agreement.

         4.  The Borrower agrees to pay all fees and out-of-pocket disbursements
incurred by the Lender in connection with this Amendment, including legal fees
incurred by the Lender in the preparation, consummation, administration and
enforcement of this Amendment.

         5.  This Amendment shall become effective only after it is fully
executed by the Borrower and the Lender. Except as amended by this Amendment,
the Credit Agreement shall remain in full force and effect in accordance with
its terms.

<PAGE>   2

         6. This Amendment is a modification only and not a novation. Except for
the above-quoted modification(s), the Credit Agreement, any agreement or
security document, and all the terms and conditions thereof, shall be and remain
in full force and effect with the changes herein deemed to be incorporated
therein. This Amendment is to be considered attached to the Credit Agreement and
made a part thereof. This Amendment shall not release or affect the liability of
any guarantor, surety or endorser of the Credit Agreement or release any owner
of collateral securing the Credit Agreement. The validity, priority and
enforceability of the Credit Agreement shall not be impaired hereby. To the
extent that any provision of this Amendment conflicts with any term or condition
set forth in the Credit Agreement, or any agreement or security document
executed in conjunction therewith, the provisions of this Amendment shall
supersede and control. Borrower acknowledges that as of the date of this
Amendment it has no offsets with respect to all amounts owed by Borrower to
Lender and Borrower waives and releases all claims which it may have against
Lender arising under the Credit Agreement on or prior to the date of this
Amendment.

         7. The Borrower acknowledges and agrees that this Amendment is limited
to the terms outlined above, and shall not be construed as an amendment of any
other terms or provisions of the Credit Agreement; The Borrower hereby
specifically ratifies and affirms the terms and provisions of the Credit
Agreement. Borrower releases Lender from any and all claims which may have
arisen, known or unknown, in connection with the Credit Agreement on or prior to
the date hereof. This Amendment shall not establish a course of dealing or be
construed as evidence of any willingness on the Lender's part to grant other or
future amendments, should any be requested.

IN WITNESS WHEREOF, the parties have entered into this Amendment as of the day
and year first above written.

BANK ONE, WISCONSIN                         ELECTRONIC TELE-COMMUNICATIONS, INC.

By:  /s/ Terry R. Sutter                    By:   /s/ Dean W. Danner
     -------------------------------              -------------------------
     Terry R. Sutter, Vice President              Dean W. Danner, President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}]]